|Year||# Div.||Div. Paid||Div. Yield||Jan||Feb||Mar||Apr||May||Jun||Jul||Aug||Sep||Oct||Nov||Dec|
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. has a strategic collaboration with Myriad Genetics, Inc. to create a kit-based version of the myChoice companion diagnostic test for international markets. The company was founded in 1998 and is headquartered in San Diego, California.
The current Price to Earnings Ratio of Illumina is 89.7.
The PE Ratio is calcluated by dividing the current Illumina share price (493.0 USD) by the earnings per share (4.5).
The current market cap of Illumina is 58.2 B USD.
The current stock price of Illumina is 493.0 USD.
The ISIN (International Securities Identification Number) of Illumina is US4523271090.
The ticker symbol of Illumina is ILMN.
The address of the Illumina HQ is 5200 Illumina Way, 92122 San Diego, CA, USA.